Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
7.15 USD | -4.03% | -7.50% | -41.58% |
05-09 | Pulse Biosciences, Inc. Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System | CI |
05-07 | Transcript : Pulse Biosciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration1st Jan change | Capi. | |
---|---|---|
-41.58% | 395M | |
+11.29% | 225B | |
+8.76% | 186B | |
+12.90% | 135B | |
+25.95% | 107B | |
+0.15% | 63.56B | |
+5.62% | 51.32B | |
+11.08% | 51.04B | |
+6.28% | 43.3B | |
+4.80% | 36.99B |
- Stock Market
- Equities
- PLSE Stock
- News Pulse Biosciences, Inc.
- Pulse Biosciences Files Premarket Notification to FDA for CellFX nsPFA Percutaneous Electrode